why choose us

First received: November 23, 2022

Clinical Trial: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent B-Cell Non-Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Brief Summary: This phase I trial tests the safety, side effects, and best dose of combination therapy with tazemetostat and belinostat in treating patients with lymphomas that have returned (relapsed) or resisted treatment (refractory).Tazemetostat is in a class of medications called EZH2 inhibitors.The EZH2 gene provides instructions for making a type of enzyme called histone methyltransferase which is involved in gene expression and cell division.Blocking EZH2 may help keep cancer cells from growing.Belinostat is in a class…

Read more